Manufacturing Plant in Oman for a Key Start-Up Material for Antibiotic Drugs

A Pharma Company in Oman is setting up a manufacturing plant for a Key Start-Up Material for Antibiotic Drugs for the Global Market. The cost of the project is US$ 93 Million (OMR 36 Million) with a Project IRR of 19.33% and Payback Period of 7 years. Investors are invited for Equity Participation. Stake available up to 80%.

GCCA conducted market analysis, feasibility study, and financial modeling for the project. We are also looking after the investor coordination and sourcing of investors for the project.